Consistent with in vitro data, the combination of standard dose BGB-290 and low-dose TMZ resulted in significantly delayed tumor progression compared to single-agent treatment in a Sdhb-deficient RENCA model (Figure 5B). Here, SDHB is linked to neoplasm.